Compare IMXI & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMXI | CELC |
|---|---|---|
| Founded | 1994 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 456.2M | 3.1B |
| IPO Year | N/A | 2017 |
| Metric | IMXI | CELC |
|---|---|---|
| Price | $15.39 | $101.35 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | $16.67 | ★ $100.13 |
| AVG Volume (30 Days) | 241.4K | ★ 980.5K |
| Earning Date | 11-10-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.29 | N/A |
| Revenue | ★ $625,123,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.95 | N/A |
| P/E Ratio | $11.91 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.58 | $7.58 |
| 52 Week High | $21.41 | $112.64 |
| Indicator | IMXI | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 62.97 | 59.72 |
| Support Level | $15.32 | $97.27 |
| Resistance Level | $15.43 | $105.14 |
| Average True Range (ATR) | 0.06 | 5.05 |
| MACD | -0.02 | -1.40 |
| Stochastic Oscillator | 40.91 | 27.26 |
International Money Express Inc is a processor of money transfer services in the USA to the Latin America and the Caribbean (LAC) corridor. The company offers wire transfer, money order, Foreign exchange, and cash checking services, while the majority of the revenue is derived from wire transfer and money order fees. The firm's business is organized around one reportable segment that provides money remittance services between the U.S. and Canada to Mexico, Guatemala, and other countries in Latin America, Africa, and Asia.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.